<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802035</url>
  </required_header>
  <id_info>
    <org_study_id>ALK29-002</org_study_id>
    <nct_id>NCT00802035</nct_id>
  </id_info>
  <brief_title>ALK29-002: A Study of Baclofen Formulations in Healthy Adults</brief_title>
  <official_title>A Phase 1, Single-Center, Open-Label Study of the Pharmacokinetics of Baclofen Formulations Administered to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics, safety, and tolerability of
      different baclofen formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant abnormal laboratory findings</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration curve (AUC)</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>IR am</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg, single dose, morning administration (immediate release [IR])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER am</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg; single dose; morning administration (extended release [ER])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER pm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg; single dose; evening administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IR pm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg; single dose; evening administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen IR</intervention_name>
    <description>30 mg; single dose</description>
    <arm_group_label>IR am</arm_group_label>
    <arm_group_label>IR pm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen ER</intervention_name>
    <description>30 mg; single dose</description>
    <arm_group_label>ER am</arm_group_label>
    <arm_group_label>ER pm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 and 65 years

          -  Body mass index of 19 to 30 kg/m2 at screening

          -  If subject is female and of childbearing potential, she must agree to use an
             acceptable method of contraception for the duration of the study

        Exclusion Criteria:

          -  Pregnancy and/or currently breastfeeding

          -  Clinical significant medical condition or observed abnormalities

          -  Acute gastrointestinal disorder or history of chronic gastrointestinal disease or
             surgery

          -  Participation in a clinical trial within 30 days before screening

          -  Known intolerance and/or hypersensitivity to baclofen or its excipients

          -  Use of alcohol-, caffeine-, or xanthine-containing products

          -  Clinically significant illness within 30 days of first study drug administration

          -  Dietary restrictions that conflict with required study meals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick A. Bieberdorf, MD, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDRA Clinical Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEDRA Clinical Research, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>December 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2008</study_first_posted>
  <last_update_submitted>August 22, 2011</last_update_submitted>
  <last_update_submitted_qc>August 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK29</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

